MYDRIACYL
Clinical safety rating: caution
Comprehensive clinical and safety monograph for MYDRIACYL (MYDRIACYL).
Anticholinergic agent that blocks muscarinic receptors in the eye, causing mydriasis and cycloplegia.
| Metabolism | Metabolized by ester hydrolysis; inactive metabolites excreted renally. |
| Excretion | Renal (approximately 70% as unchanged drug and metabolites), biliary/fecal (approximately 30%) |
| Half-life | Terminal elimination half-life is approximately 2 hours in adults; prolonged in elderly and patients with hepatic impairment |
| Protein binding | Approximately 40-60% bound to plasma proteins, primarily albumin |
| Volume of Distribution | Approximately 0.5-1.0 L/kg, indicating distribution into total body water and extensive tissue binding |
| Bioavailability | Not applicable for oral route; topical ophthalmic: systemic absorption is minimal, but detectable plasma levels occur after ocular administration |
| Onset of Action | Topical ophthalmic: mydriasis within 15-30 minutes, cycloplegia within 30-60 minutes; peak effect at 30-45 minutes |
| Duration of Action | Mydriasis 6-12 hours, cycloplegia 6-24 hours; residual effects may persist up to 48 hours in some patients |
For refraction: 1-2 drops of 0.5% or 1% solution topically in the eye(s), repeated every 5-10 minutes for up to 3 doses; for cycloplegia: 1-2 drops of 1% solution topically, repeated once after 5 minutes.
| Dosage form | SOLUTION/DROPS |
| Renal impairment | No dose adjustment required for renal impairment; minimal systemic absorption. |
| Liver impairment | No dose adjustment required for hepatic impairment; minimal systemic absorption. |
| Pediatric use | Infants: 1 drop of 0.5% solution topically, repeat every 10-15 minutes for up to 3 doses; children: 1 drop of 0.5% or 1% solution topically, repeat every 5-10 minutes for up to 3 doses. Use lower concentrations (0.5%) in infants and young children to minimize systemic effects. |
| Geriatric use | Use lowest effective concentration (0.5%) and minimal number of drops; monitor for systemic anticholinergic effects due to increased sensitivity. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for MYDRIACYL (MYDRIACYL).
| Breastfeeding | It is not known if tropicamide is excreted in human breast milk. Due to potential for serious adverse reactions in nursing infants, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother. M/P ratio is not available. |
| Teratogenic Risk | Pregnancy Category C. No adequate and well-controlled studies in pregnant women. Tropicamide crosses the placenta. Animal studies have shown no evidence of teratogenicity at ophthalmic doses, but systemic exposure to high doses in rats was associated with fetal toxicity (increased resorptions, delayed ossification). Risk cannot be ruled out; use only if clearly needed, especially during first trimester. |
■ FDA Black Box Warning
None.
| Serious Effects |
Hypersensitivity to tropicamide; patients with narrow-angle glaucoma; concurrent use with anticholinergic drugs.
| Precautions | May precipitate acute angle-closure glaucoma; avoid use in patients with narrow angles. Use with caution in elderly, children, and patients with cardiovascular disease. |
Loading safety data…
| Fetal Monitoring | No specific monitoring is routinely required for pregnant patients receiving topical ophthalmic tropicamide. However, due to potential systemic anticholinergic effects, monitor for maternal tachycardia, blurred vision, or central nervous system effects (dizziness, confusion) especially with repeated or high-dose administration. |
| Fertility Effects | No human studies on fertility effects. Animal studies have not been conducted to evaluate the effect on fertility. No known impact on fertility from topical ophthalmic use. |